Profile data is unavailable for this security.
About the company
Abbott India Limited is an India-based company engaged in the pharmaceuticals business. The Company is involved in product development, manufacturing, and sales of healthcare products. It operates in a single reportable business segment, which is Pharmaceuticals. It distributes products and solutions in multiple therapeutic categories such as women's health, gastroenterology, cardiology, metabolic disorders, Central Nervous System, Vaccines, Multi-Specialty, and primary care. Its products include Colospa (irritable bowel disease), Ganaton (gastrointestinal motility), Librax (irritable bowel disease), Thyronorm (hypothyroidism), Duphaston (miscarriage and IVF), Duphalac (constipation), Digene (antacid), Prothiaden (pain and depression), Influvac (prevention of influenza), Cremaffin Plus (Constipation), Pankreoflat (indigestion), Brufen P (fever), and Duvadilan (preterm labor). It offers various products under brands such as Similac, PediaSure, Pedialyte, EleCare, Ensure, and Glucerna.
- Revenue in INR (TTM)59.28bn
- Net income in INR12.39bn
- Incorporated1944
- Employees3.81k
- LocationAbbott India Ltd3-4 Corporate ParkSion-Trombay Road, ChemburMUMBAI 400051IndiaIND
- Phone+91 2 250461000
- Fax+91 2 267978727
- Websitehttps://www.abbott.co.in/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Suven Pharmaceuticals Ltd | 9.34bn | 2.40bn | 325.27bn | 1.05k | 135.12 | -- | 109.92 | 34.81 | 9.46 | 9.46 | 36.75 | -- | -- | -- | -- | 8,883,019.00 | -- | 23.17 | -- | 26.20 | 56.59 | 58.85 | 25.73 | 33.21 | -- | 33.74 | -- | 18.63 | -21.56 | 22.71 | -26.99 | 22.41 | -1.83 | -- |
| Piramal Pharma Ltd | 87.04bn | 453.30m | 333.24bn | 6.72k | 741.05 | 4.21 | 41.42 | 3.83 | 0.3407 | 0.3407 | 66.36 | 59.91 | 0.5799 | 1.40 | 4.88 | 12,954,040.00 | 0.302 | -- | 0.428 | -- | 63.69 | -- | 0.5208 | -- | 0.5603 | 7.49 | 0.3771 | -- | 15.39 | -- | 109.56 | -- | -- | -- |
| Ajanta Pharma Ltd | 44.91bn | 8.75bn | 374.32bn | 7.84k | 43.09 | 10.18 | 36.99 | 8.34 | 69.55 | 69.55 | 356.94 | 294.36 | 0.9738 | 1.33 | 4.16 | 5,725,128.00 | 18.97 | 16.61 | 23.29 | 20.47 | 75.77 | 73.22 | 19.48 | 19.31 | 2.13 | 49.88 | 0.0088 | 31.20 | 12.45 | 15.41 | 38.81 | 16.10 | -14.97 | 10.76 |
| IPCA Laboratories Ltd | 82.12bn | 5.77bn | 396.34bn | 17.34k | 68.71 | -- | 41.77 | 4.83 | 22.74 | 22.74 | 323.71 | -- | -- | -- | -- | 4,737,502.00 | -- | 10.33 | -- | 13.52 | 67.08 | 59.16 | 6.84 | 12.25 | -- | 15.41 | -- | 12.86 | 23.39 | 15.35 | 16.13 | 4.24 | 17.90 | 21.67 |
| GlaxoSmithKline Pharmaceuticals Limited | 35.60bn | 6.75bn | 453.03bn | 3.21k | 67.53 | 27.08 | 60.93 | 12.72 | 39.60 | 39.60 | 209.31 | 98.74 | 1.01 | 2.59 | 14.85 | 11,088,370.00 | 19.24 | 11.01 | 36.09 | 17.88 | 61.70 | 55.77 | 18.96 | 12.25 | 1.38 | 554.80 | 0.0088 | 192.07 | 6.21 | 2.00 | -2.91 | 5.78 | -36.02 | 9.86 |
| Glenmark Pharmaceuticals Ltd | 120.21bn | -15.73bn | 471.25bn | 14.99k | -- | -- | -- | 3.92 | -55.78 | -46.50 | 425.96 | -- | -- | -- | -- | 8,020,026.00 | -- | 1.02 | -- | 1.43 | 63.93 | 59.47 | -12.71 | 1.43 | -- | 1.78 | -- | 56.98 | 1.98 | 3.67 | -1,018.93 | -- | -5.89 | 4.56 |
| Abbott India Ltd | 59.28bn | 12.39bn | 603.63bn | 3.81k | 48.72 | -- | 46.03 | 10.18 | 583.08 | 583.08 | 2,789.54 | -- | -- | -- | -- | 15,541,480.00 | -- | 20.92 | -- | 28.59 | 45.28 | 44.20 | 20.90 | 17.26 | -- | 119.46 | -- | 77.06 | 9.35 | 9.72 | 26.52 | 21.68 | 31.08 | 52.32 |
| Alkem Laboratories Ltd | 127.32bn | 20.54bn | 692.95bn | 17.28k | 33.73 | -- | 29.10 | 5.44 | 171.81 | 171.81 | 1,064.87 | -- | -- | -- | -- | 7,369,150.00 | -- | 11.88 | -- | 17.50 | 62.21 | 59.26 | 16.29 | 13.94 | -- | 9.12 | -- | 29.82 | 9.21 | 11.48 | 82.47 | 18.75 | -13.30 | 20.11 |
| Aurobindo Pharma Ltd | 297.18bn | 35.21bn | 816.11bn | 8.80k | 23.37 | -- | 16.04 | 2.75 | 60.12 | 60.12 | 507.19 | -- | -- | -- | -- | 33,782,390.00 | -- | 9.24 | -- | 13.43 | 57.87 | 53.30 | 11.84 | 12.72 | -- | 13.17 | -- | 8.64 | 16.68 | 8.19 | 64.62 | 6.06 | 17.96 | 12.47 |
| Holder | Shares | % Held |
|---|---|---|
| Canara Robeco Asset Management Co. Ltd.as of 30 Sep 2024 | 268.30k | 1.26% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 30 Sep 2024 | 201.35k | 0.95% |
| Axis Asset Management Co. Ltd.as of 30 Sep 2024 | 165.59k | 0.78% |
| PGIM India Asset Management Pvt Ltd.as of 30 Sep 2024 | 69.77k | 0.33% |
| Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 30 Sep 2024 | 52.33k | 0.25% |
| Franklin Templeton Asset Management (India) Pvt Ltd.as of 30 Sep 2024 | 52.30k | 0.25% |
| UTI Asset Management Co. Ltd. (Investment Management)as of 30 Sep 2024 | 44.01k | 0.21% |
| Dimensional Fund Advisors LPas of 31 Jul 2024 | 41.78k | 0.20% |
| ICICI Prudential Asset Management Co. Ltd.as of 30 Sep 2024 | 31.59k | 0.15% |
| Mahindra Manulife Investment Management Pvt Ltd.as of 30 Sep 2024 | 24.40k | 0.12% |
